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Abstract
Warfarin is the most commonly used oral anticoagulant medication given as a
prophylaxis and/or treatment of venous and arterial thromboembolic disorders.
Warfarin doses vary up to 10-fold among patients due to pharmacokinetics,
pharmacodynamics and pharmacogenomics factors. In addition, Warfarin has a low
therapeutic index with the risk of developing serious side effects such as severe
bleeding or failure of therapy. Therefore, the main challenge to achieve the
therapeutic goal in Warfarin treatment is estimating the appropriate dose for each
patient. It is estimated that pharmacogenomic factors contribute to more than 60% of
dose variability. The gene encoding for the target enzyme of Warfarin, vitamin K
epoxide reductase complex 1 (VKORC1), is a highly polymorphic gene and
contributes to about 30% of this variability. The US Food and Drug Administration
(FDA) recommends genetic testing to determine the VKORC1 genotype prior to
using Warfarin. However, there are no data on VKORC1 alleles and genotypes or
their frequencies among Emiratis. Therefore, the current approach is trial and error
with warfarin doses which might lead to some serious complications for patients
receiving this medication. In this thesis, we used PCR amplification and direct DNA
Sanger sequencing to genotype the two most important variants in VKORC1 genes
(namely, rs9923231 and rs7294). The sample consisted of 117 healthy Emirati
nationals as control and 96 patients on stable Warfarin therapy. The alleles and
genotypes frequencies were determined for both groups. In addition, the daily
Warfarin maintenance dose for patients was examined for associations with the
VKORC1 genotypes at the rs9923231 and rs7294positions. There was no significant
difference in allele frequencies between the controls and patients for either SNP. The
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genotypes frequencies for rs9923231 were 25%, 48.4%, 26% for GG, GA, AA
genotypes, respectively. In addition, genotypes frequencies for rs7294 variant were
44%, 44%, 12% for GG, GA, AA genotypes, respectively. Crucially, both VKORC1
polymorphisms were found to be strongly associated with the Warfarin doses
required to achieve the target international normalized ratio INR (p < 0.0001). The
results of this study confirm the suitability of VKORC1 genotyping to guide the use
of the appropriate Warfarin dosage for Emiratis.
Keywords: Warfarin dosage, rs9923231, rs7294, VKORC1, pharmacogenetics of
Emiratis, Pharmacogenomics
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)Title and Abstract (in Arabic
تعدد االنماط الجينية لجين  VKORC1على الموقعين  rs9923231و  rs7294بين مواطني االمارات
وتاثيرات ذلك على جرعة عقار الوارفرين
هذه الدراسة تعنى بالصيدلة الجينية وذلك بدراسة تاثير المتغيرات الجينية في انزيم  VKORC1على جرعة
عقار الوارفرين وهو دواء شائع لعالج التخثرات الدموية وتسعى هذه الرسالة لمعرفة تردد أهم المتغيرات
الجينية في هذا االنزيم في مواطني دولة االمارات ودراسة حقيقة تأثير هذه االنماط الجينية في كل من موقع
 rs9923231و  rs7294وطريقة عمل البحث تمت بجمع عينات المارتين اصحاء عدد  111ومرضى يتم
عالجهم بعقار الوارفرين عدد  69وذلك بعد موافقة االفراد المشاركين بالدراسة وبعد جمع عينات الدم تم
استخالص مادة الدي ان اي وعمل دراسة جينية عن طريق معرفة السلسلة الجينينه في كل من الموقع
 rs9923231و  rs7294واخذ معلومات عن جرعة المرضى اليومية من خالل ملفهم الطبي أدت نتائج هذه
الرسالة بمعرفة تردد االنماط الجينية في موقع  rs9923231و كان تردد النمط الجيني ل  GGهو  % 3.52و
تردد  %96 GAوتردد  AAهو  % 39ولم يالحظ اي فرق بين تردد االنماط الجينية بين المرضى
واالشخاص االحصاء وفي موقع  rs7294كان تردد النمط الجيني  GGهو  %99وهو نفس تردد النمط الجيني
GAوأما النمط الجيني AAكان االقل بتردد  % 13و للموقعين الجيني اثر كبير في تحديد الجرعة حسب
التحليل االحصائي للدراسة اال ان الموقع  rs9923231كان له اثر اقوى بالتنبؤ بالجرعة مقارنة بالموقع الجيني
 rs7294وتعد هذه اول دراسة لتحديد تردد االنماط الجينيةالنزيم  VKORC1في دولة االمارات العربية
ودراسة اهمية هذا التغير في االنماط الجينية على المرضى الذين يتناولون عقار الوارفرين 5
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CHAPTER 1: INTRODUCTION

1.1 Human Genetic Variation and Drug Response
Inter-individual variation in drug response and the development of drug side effects
among patients are major challenges in clinical pharmacology. Several factors
usually contribute to this variability including age, weight, level of organ function,
co-medications, disease itself, concomitant diseases, cultural and racial factors
including genetics, smoking, alcohol consumption and dietary preferences [1].
However, for some medications, the genetic variation is the major contributor with
up to 95% in some cases [2].
All humans are genetically identical in about 99% of their genomes. The
approximately 1% differences from person to person are mainly in the forms of
single nucleotide polymorphisms (SNPs), copy number variations (CNVs) and
variation in the number of tandem repeats [3]. A SNP is a change in the sequence of
a single nucleotide base[4]. On average, a SNP appears every 1250 bp of DNA in the
human genome and they account for about 90% of human genetic variation [3].
Generally, there are numerous polymorphic variants for most genes among the total
world population and consequently it is often hard to know which variant is the
“true” wild type sequence [5].
SNPs in coding genes of drug metabolizing enzymes, drug receptors, drug binding
proteins and drug transporters may cause variability in the structures and/or activities
of the encoded proteins [4]. In addition, in some instances SNPs in genes encoding
drug-metabolizing enzymes or proteins involved in handling medications may result

2

in lower mRNA expressions and hence may cause lower enzymic activity or
alteration in receptor function [6]. On the other hand, duplications or multiplications
of active genes results in higher mRNA levels and thus higher enzyme expression
that lead to an increase in enzymic activity and faster metabolism of the medications
handled by that particular enzyme [6].
SNPs are responsible for a large proportion of the genetic contribution to variation in
drug response and therefore they are key targets for pharmacogenetics and
pharmacogenomics studies [4].

1.2 Pharmacogenetics and Pharmacogenomics
Pharmacogenetics is the inherent response or the genetically determined variation in
drug response. According to the FDA definition, it is the study of variation in DNA
sequences

that

can

affect

drug

response.

Recently,

the

discipline

of

“pharmacogenomics” has been defined as the study of variation in DNA sequences
and RNA characteristics at the whole genome level that can affect drug response. In
other words, pharmacogenomics deals with inter-individual variation at whole
genome level with specific expression products and functions that can be used to
predict the appropriate treatment for individual patients [7]. To simplify the
difference between pharmacogenetics and pharmacogenomics, pharmacogenetics can
be defined as the effect of inter-indvidual differences caused by variation in a single
gene whereas pharmacogenomics relates to the involvement of many genes or the
whole genome in the variability in drug response [7]
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To reiterate, genetic variation in genes encoding drug metabolizing enzymes, drug
transporters, drug-binding proteins and receptors can all cause variation in the
phenotypic response and thus are key targets for studying the pharmacogenetics and
pharmacogenomics of most medications [8]
Most efforts to study the involvement of genetic variation on dose requirements and
responses of patients to drugs were carried out as a result of adverse drug reactions
and side effects. These adverse drug reactions are estimated to be the 4th or 6th
leading cause of death in the USA and to be the underlying cause of approximately
10% of inpatient admissions to hospitals. It has been estimated that approximately
2,216,000 patients suffer from serious side effects of medication leading to an
estimated 106,000 patient deaths in the USA alone [9]. In the UK, adverse drug
reactions cost approximately £380 million a year. In addition, an NIH report
indicates that one out of ten inpatient admissions are for cases of adverse drug
reaction [10].
Study carried out in Saudi Arabia showed that healthcare professionals lack the
awareness of the importance of recording adverse drug reactions and analyze related
the outcomes [11]. Another Study carried out in the United Arab Emirates (UAE)
concluded the prevalence of inadequate knowledge of adverse drug reaction
reporting procedures as a major barrier in recording adverse drug reactions [12].
More than 50% of adverse drug reactions relate to an administered dose [1] and 59%
of drugs metabolized by polymorphic enzymes have been reported to have serious
adverse effects [13].
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Therefore, pharmacogenetic and pharmacogenomics studies aim to reduce the risk of
medication usage by predicting the optimal dose and the risk of developing side
effects associated with particular medication in individual patients. In other words, it
aims to identify patients at risk of developing adverse side effects by determining
their genetic variants in the genes relevant to the proscribed medication [14].
Over the years, the genetically determined variation in drug response has become
increasingly recognized by physicians, geneticists and pharmaceutical researchers.
Therefore, there is an urgent need for pharmacogenetics and pharmacogenomics
research to determine the appropriate dose for each patient. Consequently,
pharmacogenetic testing may open the door for physicians to predict optimal doses
and responses to individual medications given to patients.

1.3 Warfarin: Historical Overview, Action Mechanism, Clinical Applications
and Associated Side Effects
In the early 1920s, an outbreak of unknown cattle disease was observed in the United
States and Canada. Severe spontaneous hemorrhages occurred to cattle and some
died after castration or dehorning. Prior to that, these procedures had been performed
with no of excessive bleeding. Investigation autopsies of dead animals revealed that
the animals bled to death [15]. One year later, a Canadian veterinary pathologist
called Frank Schofield attributed the cause of death to the ingestion of hay made
from spoiled sweet clover. Subsequent experimental testing on rabbits determined
that spoiled clover worked as a potent anticoagulant [15].
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In 1929, another veterinarian called L.M. Roderick investigated the cause of bleeding
and suggested that it was caused by the decrease in the function of prothrombin [16].
Subsequently, Henrik Dam from Denmark discovered that vitamin K deficiency can
cause a hemorrhagic disease in chickens with lower prothrombin levels similar to the
cases reported in cattle in North America [17]. Several years later, a trial was
performed to make potent toxins out of spoiled sweet clover at Wisconsin University
[18]. In particular, in 1933 Karl Paul Link and his team were able to isolate the toxic
hemorrhagic substance [19]. Link and his group also identified the chemical structure
of this compound as 3, 3,-Methylene-Bis-(4-Hydroxycoumarin) [20]. Link later
named this compound Dicoumarol, which is a fermentation of the plant molecule
Coumarin [21], that is present in many plants and gives the sweet smell of fresh grass
and hay. Interestingly, the name “sweet clover” comes from its high content of
Coumarin [18].
The Coumarin molecule itself has no anticoagulant properties but this activity results
from its fermentation by fungi. Link donated the patents for Dicoumarol to the
Wisconsin Alumni Research Foundation (WARF) in 1939 and continued his work on
developing potent anticoagulants to be used as rat poison [21]. In 1940, he was able
to achieve his goal with the most potent rodenticide which he named “Warfarin”
[21]. It was believed that Warfarin would be extremely toxic to humans as well as
rats until suicidal attempts in 1952 ended up with hospitalization followed by full
recovery of the patient. Crucially, the patient was treated with Vitamin K to
antagonize the effect of Warfarin [22]. Further studies demonstrated the possible use
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of Warfarin as a treatment in coagulation conditions [21]. Numerous studies were
carried out to establish the exact effects of Warfarin on humans [22].
Reports of variable responses by humans to fixed doses of Warfarin were
documented very early after its initial use [23]. Today Warfarin is the most widely
prescribed oral anticoagulant worldwide due to its effectiveness, low cost and
convenient oral dose [24].
Vitamin K play a role in the coagulation cascade since the reduction of vitamin K
leads to the activation of clotting factors through the gama carboxylation of these
coagulation proteins mostly factors II (Prothrombin), VII, IX, X, protein C and
Protein S. Understandably, these proteins are called Vitamin K dependent proteins.
Once they are carboxylated, they get transformed into their active forms that lead to a
coagulation cascade [25] .
Vitamin K reduced by Vitamin K expoxide reductase (VKOR) functions as a
recycling enzyme for Vitamin K. The basic action mechanism of Warfarin is the
inhibition of Vitamin K expoxide reductase (VKOR) enzyme and thus the impairing
of the synthesis of clotting factors [26], as illustrated in Figure 1.
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Figure 1. Effect of Warfarin on VKORC activity and Vitamin K cycle. [26].

There are two isomer forms of Warfarin, the S and the R isomers as shown in Figure
2. The S-isomer is five times more potent than the R-isomer in inhibiting VKORC
[25].
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(A) S –Warfarin

(B ) R- Warfarin

Figure 2. Molecular Structure of (A) S -Warfarin and (B) R- Warfarin. [27].
The effect of Warfarin therapy on a blood coagulation profile is measured by the
International Normalized Ratio (INR) which is a universal conversion of
prothrombin time test [28].
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In 1990, the INR was adopted as an indicator to monitor Warfarin effects. INR
corrects for variation that come with different thromboplastin reagents from different
hospitals and laboratories worldwide, and for new batches of reagents [29].
To avoid hemorrhage (the principal adverse side effect of Warfarin), frequent
monitoring and adjustment to the anticoagulant effect of the drug is necessary.
This depends on the INR result, which can be obtained by a Prothrombin Time test
(PT test) for monitoring and evaluating the effect of vitamin K antagonist (VKA)
therapies and is a reliable measure of extrinsic pathways of coagulation [29], [30].
In order to achieve treatment goals with anticoagulation therapy using a Vitamin K
antagonist such as Warfarin, patients need to maintain their target INR range. This
goal can be achieved with regular monitoring and appropriate adjustment to a
Warfarin dose [30]. Target INR intervals vary according to Warfarin indication, but
in general an INR value of <2.0 is associated with increased risk of a thrombotic
event while INR value of >4.0 is associated with increased risk of a bleeding crisis.
Therefore, current recommendations suggesting an INR range of between 2.0 and 3.0
for patients with atrial fibrillation and venous thromboembolism [30], [31] and an
INR range of 2.5-3.5 for patients with mechanical heart valves [32].
Warfarin does not exert an instant effect as an antithrombotic/anticoagulant
medication as several doses are required to show an effect. The delayed effect is due
to pre-existing Vitamin K-dependent clotting factors that must be catabolized by the
body while at the same time inhibiting the activation of newly made Vitamin Kdependent clotting factors and for total protection from thrombus formation or
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complications. However, the orally administered anticoagulant Warfarin can be
given with a rapid acting anticoagulant such as Heparin or Low Molecular Weight
Heparin [30].
Warfarin is an oral anticoagulant that is mostly prescribed to prevent the progression
or recurrence of acute deep vein thrombosis or pulmonary embolism as a second
option after using Heparin. It is also used to prevent venous thromboembolism
during surgeries such as orthopaedic or gynecologic surgeries and as a prophylactic
treatment in chronic atrial fibrillation, acute myocardial infarction, prosthetic heart
valve and stroke [29], [31].
Although it is widely used, Warfarin has one major limitation. It is a drug with a low
therapeutic index and is listed among the top 10 agents associated with serious side
effects such as bleeding. Approximately 20% of patients using Warfarin suffer from
bleeding, thromboembolic events (TEE), inpatient hospitalization and emergency
admission or sometimes treatment failure and the complication of coagulation. It
should always be given with safety controls as indicated on the drug label [29], [33].
Besides hemorrhages, other minor side effects have been observed such as skin
lesions and necrosis. Another problem associated with Warfarin use is the numerous
drug-drug interactions and its teratogenic effect. Therefore, Warfarin should never be
used during pregnancy due to associated birth defects and abortion [29].
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1.4 Factors Influencing Variability in Warfarin Dose Requirements
Variability in warfarin doses has been extensively documented. This variability can
be attributed to combinations of genetic and non-genetic factors as detailed in the
following sections.

1.4.1 Non-Genetic Factors
As already mentioned, Warfarin is a drug with a low therapeutic index and therefore,
small increases in dosage may cause serious side effects while a lower than
therapeutic dose will be ineffective. Maintenance doses of Warfarin required to
safely achieve stable anticoagulation can vary across populations by up to twenty
fold with an average dose of 5 mg/day. However, some individuals require doses of 1
mg/day or less whilst others may require up to 20 mg/day or even more to achieve
the desired INR target [29]. The identification of the maintenance dose is important
to avoid the risk of bleeding that comes with Warfarin use, depending on the comorbid conditions of the patient [34]. Significant efforts and research have been
undertaken to avoid the development of side effects by estimating the exact safe
dosage as Warfarin is the most often cited reason for mortality caused by medication
[33]. It is also the second leading cause of drug emergency admissions in the United
States [35]. It is worth noting that the most often cited life-threatening complications
of Warfarin use are gastrointestinal bleeding and intracranial hemorrhage [36].
Many co-medications can change the required dose of Warfarin and the main
mechanism is either by induction or inhibition of hepatic CYP2C9 or by competition
with the plasma protein binding site for Warfarin [29]. Drugs that can induce the
expression of CYP2C9 cause an increase in the enzymic action of CYP2C9 and
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possibly the induction of other metabolizing liver enzymes [37]. examples of such
drugs

include

alcohol,

barbiturates,

glutethimide,

grisofulvin,

rifampin,

carbamazepine, phenobarbital, phenytoin and the herbal antidepressant st. john`s
wort. Chronic alcohol consumption has the same action on CYP2C9 enzymic
induction [29]. Patients using enzyme inducer drugs along with Warfarin require
higher doses of Warfarin [38].
Other medication may cause the opposite effect on the CYP2C9 enzyme as they may
inhibit its catalytic activity [38]. For example, azole antifungal medications (e.g.
fluconazole and voriconazole), amiodarone, sulfamethoxazole (found in the common
combination antibiotic trimethoprim-sulfamethoxazole), statins (e.g. fluvastatin and
lovastatin), and some antidepressants (e.g. fluvoxamine and sertraline), cimitdine,
chloramaphenicol, cotrimoxazol, disuulfiram, metronidazole, phenylbuazone, and
acute alcohol intoxication all have inhibitory effects on CYP2C9. Patients using a
CYP2C9 inhibitor medication concomitantly with Warfarin need lower doses of the
anticoagulant since the metabolism and the evacuation of Warfarin will be reduced
as a result of the decrease in CYP2C9 function and thus increase the risk of an
accumulation of Warfarin to toxic levels. In these cases, anticoagulant overdose is a
major risk. In terms of drug-drug interactions, among all these medications, the drugs
with a strong effect on Warfarin dosage are amiodarone and statins [39], [40], [29].
In

order

to

predict

Warfarin

dosage

the

Warfarin

dosing

website

(www.warfarindosing.com) developed an online calculator that takes into account
possible factors that can cause changes in Warfarin dosage especially concomitant
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therapy with amiodarone, statins, azole antifungals, sulfamethoxazole and
trimethoprim as factors to predict the most appropriate Warfarin dose [29].
Vitamin K deficiency, a hepatic disease that impairs a synthesis of clotting factors,
any disease or medication that can impair organ function that controls Warfarin
metabolism, or a hypermetabolic state that elevates Vitamin K levels depending on
clotting factors and catabolism are all factors that can contribute to a
hypoprothrombinemic state in patients and therefore they affect the required dose
[29].
Warfarin is a water soluble molecule that is quickly absorbed after oral intake with
peak plasma concentration obtained from 60 to 90 minutes and 100% bioavailability
with little individual variation in bioavailability. However, food may delay
absorption without affecting the extent of absorption and 99% is bound to plasma
albumin and drugs with a higher affinity to a binding site for albumin like
sulfonamides that can displace Warfarin from Plasma albumin leading to an
elevation of Warfarin activity [29]. In addition, Lovastatin and Indomethacin
compete with Warfarin for plasma protein binding sites and therefore increase the of
free activity of Warfarin and potentiate its action [29].

1.4.2 Genetic Factors
There are several genetic factors that can affect a patient’s Warfarin dose.
Polymorphisms in cytochrome P-450 C9 (CYP2C9), the enzyme responsible for
Warfarin metabolism, are major contributors. However, it was estimated that genetic
variation in the gene encoding for this enzyme account for approximately 12% of the
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changes in the maintenance dose of Warfarin [41],[42]. In addition, genetic variation
of VKORC1, the gene encoding Warfarin site of action (Vitamin K Epoxide
Reductase), account for up to 30% of the inter-individual variation in maintenance
doses [43], [44]. More details on the contribution of VKORC1and CYP2C9 will be
provided in the next section (1.5.).
Researchers attempted to identify other genes involved in the dose variation of
Warfarin among individuals identified CYP4F2 as a contributory factor to variations
in dose. The CYP4F2 enzyme is widely distributed in human livers and other tissues.
Its function is to catalyze the hydroxylation of Lipoxygenase-derived eicosanoids as
well as the oxidation of Vitamin K [45]. A genetic variation in CYP4F2 that results
in the replacement of a valine amino acid at position 433 by methionine (p.V433M)
leads to a decrease in the oxidation of Vitamin K. This in turn causes an elevation in
the concentration of vitamin K in hepatic cells and therefore patients on Warfarin
with this variant needs higher doses [46]. The total effects of CYP4F2 on Warfarin
dosage accounts for about 1-2% of the change in dose among individuals [47]–[49].
Studies on GGCX gene found a correlation of a microsatellite variant with Warfarin
sensitivity [26]. This enzyme has a critical role in the vitamin K cycle as it catalyzes
the gamma carboxylation of vitamin K dependent proteins in the coagulation cascade
as shown in Figure 3.
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Figure 3. Role of γ-glutamyl carboxylase (GGCX) in Vitamin K cycle [50].
GGCX catalyzes the posttranslational carboxylation of specific glutamic acid
residues to γ-carboxyglutamic acid (gla) in a variety of vitamin K–dependent
proteins [50].
This gene is located on chromosome 2 and encodes for gamma-glutamyl carboxylase
enzyme (GGCX). Variants in GGCX require about 6% reduction in Warfarin dosage
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and the total effect of GCCX gene accounts for <1% of the variation in Warfarin dose
requirements [51].
Genotype information and clinical factors such as age and weight are important
predictors in Warfarin dosing calculations to select the optimal dose for the patients
at the start of therapy [52].
A different Vitamin K intake for each patient is also a factor in Warfarin sensitivity
and resistance. A high intake of vitamin K reduces the response to the medication
[53]. In general, Vitamin K refers to a family of vitamins K1 (Phylloquinone) and K2
(Menaquinone) that are mainly involved in human health and disease [54]. Vitamin
K1 comes from dietary sources such as the green leaves of some vegetables,
vegetable oils and supplements. The majority of Vitamin K stores in the human body
consist of Vitamin K1 [55].
In addition, gut bacteria synthesize Vitamin K2 which has a limited role in providing
the human body with daily requirement of Vitamin K in comparison to Vitamin K1.
There are four main fat soluble vitamins (A, D, E and K). Vitamin K has the lowest
total stores in the body hence several weeks of restricted dietary intake of Vitamin K
can completely deplete all the Vitamin K stores in the body [53]. Studies on the
effects of different Vitamin K intake levels on Warfarin requirements found that it is
a significant contributor to variation in the initial Warfarin dose [56].
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1.5 The Pharmacogenetics and Pharmacogenomics of Warfarin
1.5.1 Cytochrome P450 Enzymes
Metabolic elimination of most current drugs is largely mediated by the function of
cytochrome P450 proteins. This enzyme system is encoded by many genes. The
enzymes expressed are mainly found in the liver and they play key roles in drug and
other xenobiotic metabolisms [57]. The CYP system is very important for the
detoxification process as it eliminates foreign substances. In addition to their
involvement in the metabolism of lipophilic compounds involving oxidation, the
CYP system is involved in the metabolism of endogenous substrates such as sterols,
steroids, eicosanoids, serotonin, bile acids, Vitamin D, retinoid, fatty acids and
uroporphyrogens [57].
In every species there are 270 cytochrome P450s (CYPs). However, only 57 CYP
genes and 33 pseudogenes are found in the human genome. These are organized in
18 families and 42 subfamilies. of all the CYP families only 3 families (families 1, 2
and 3) are responsible for drug metabolism. CYP2C9 constitutes approximately
18% of the total CYP protein content in the human liver [38], [58].
CYP2C9 is one of the most important enzymes in drug metabolism as it metabolizes
approximately 60 drugs. There are inter-ethnic and inter-individual variations in drug
metabolisms with the occurrence of genetic polymorphisms in the CYP2C9 gene
[59]–[61]. CYP2C9 is involved in the metabolism of 10-20% of all the clinically
important drugs worldwide such as Warfarin and other coumarin anticoagulants,
losartan, tolbutamide, sulfonylurea drugs, angiotensin ii blockers, nonsteroidal antiinflammatory drugs (NSAIDS), Phenytoin and glipizide [47], [60], [61].
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There are four distinctive groups of CYP phenotypes arranged according to their
metabolic capacity. Extensive metabolizers (EM) with regular metabolic capacity,
low metabolizers (LM) with low metabolic activity, intermediate metabolizers (IM)
that shows intermediate activity, while the ultra-rapid metabolizers (UM) show the
highest metabolic activity group [62].
CYP2C9 polymorphisms are important determinants of the Warfarin dosage as the
presence of CYP2C9 polymorphisms is associated with a reduction in the metabolism
of S-Warfarin [63], [64]. Thirty four CYP2C9 variant alleles have been reported in
the world population so far (http://www.cypalleles.ki.se/). CYP2C9*1 is a wild-type
allele, and there are two important single nucleotide variations that result in missense
mutations in the coding region of the CYP2C9 gene. The CYP2C9*2 allele (C430T
in exon 3) results in the replacement of an arginine at the amino acid position 144 by
cysteine (p.R144C).
This is a functionally important substitution as this mutation leads to the reduction of
the catalytic activity to 12% compared to the wild-type enzyme. Additionally, the
CYP2C9*3 allele (A1075C of exon 7) leads to the substitution of a leucine residue
by isoleucine at position 359 (p.L359I). This mutation is associated with a reduction
in the catalytic activity to about 5% of the wild type. Studies have shown that the
CYP2C9*3 allele is associated with lower intrinsic clearance of the Warfarin
substrate and a lesser enzyme activity (<5%) than CYP2C9*2. Both CYP2C9*2 and
*3 genetic variants are widespread in caucasian populations, with allele frequencies
varying from 3.3% to 18% [65], [66].
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As above, both CYP2C9*2 and *3 variants encode for enzymes with reduced
catalytic activities that result in impaired hydroxylation of Warfarin compared to the
wild-type CYP2C9 enzyme. Therefore, lower doses of Warfarin are required in
individuals with these alleles. It was observed that a longer time is required to
achieve a stable Warfarin dosage and therefore these patients are at higher risk
during the initial phase of Warfarin therapy [47], [63].
In caucasian populations the frequency of the CYP2C9*1/*1 genotype is 65-70%, the
CYP2C9*1/*2 genotype is 15-20%, the CYP2C9*1/*3 genotype is 8-10%. Poor
metabolizer

genotype

frequencies

for

CYP2C9*2/*2,

CYP2C9*3/*3

and

CYP2C9*2/*3 are between 1 and 2% each [63], [64].

1.5.2 Vitamin K Epoxide Reductase (VKORC1)
The Vitamin K epoxide reductase VKOC1 enzyme is involved in the biosynthesis of
Vitamin K dependent coagulation factors through the Vitamin K regeneration
process. On the other hand, Vitamin K plays a key role as a cofactor in gamma
carboxylation of several clotting factors (II, VII, IX and X) and proteins C and S that
are all involved in coagulation. The Vitamin K epoxide reductase VKOC1 enzyme is
Warfarin sensitive and can be inhibited by preventing the Vitamin K recycling
process [67]–[69] as shown in Figure 4.
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Figure 4. Warfarin effect as Vitamin K anticoagulant. [44]
Warfarin inhibits Vitamin K recycling and thus preventing the formation of more
Vitamin K dependent coagulation factors [44].
The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit-1, a
small transmembrane protein of the endoplasmic reticulum. VKORC1 [MIM
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608547] is the key enzyme of the Vitamin K cycle and the molecular site for the
action of Vitamin K antagonists (Coumarins) including Warfarin, Acenocoumarol
and Phenprocoumon, which are used for long-term treatment of thromboembolic
diseases [44], [70].
It has been known for many years that the action of Warfarin involved Vitamin K yet
without full understanding of the exact nature of its involvement until 2004. The
exact molecular target of Warfarin was discovered by two independent research
groups when they found a protein that was later named as Vitamin K epoxide
reductase complex subunit 1 (VKORC1) [68], [71].

This gene is located on

chromosome 16p11 as shown in figure5.

Figure 5. Chromosomal

location of

VKORC1 gene on the short arm of

chromosome 16. [72].
The first group of researchers, Li and colleagues tested the ability of candidate genes
to inhibit vitamin K epoxide reductase (VKOR) activity in human cells by using
short interfering (siRNA) pools against these genes to observe gene activity. Li and
colleagues expressed the gene in insect cells and described the gene as coding for a
163-amino acid protein with 3 exons. They also showed that the protein contained 1
to 3 transmembrane domains and 7 cysteine residues, 5 of which are conserved
among human, mouse, rat, zebrafish, Xenopus, and Anopheles [68].
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In same the year, Rost and colleagues cloned the VKORC1 gene and described it as a
gene encoding a protein of 163 amino acids with a mass of 18KDa [69]. It was
mainly expressed in fetal and adult livers and to a lesser extents in fetal hearts,
kidneys, lungs, adult hearts and the pancreas. The enzyme is associated with the
endoplasmic reticulum [71].
Rost colleagues also studied the involvement of VKORC1 in the combined deficiency
of Vitamin-K-dependent clotting factor type 2 (VKCFD2; OMIM 607473), and
resistance to Coumarin oral anticoagulant drugs (Warfarin resistance, WR; OMIM
122700). They found that it correlated with pathological conditions and Warfarin
resistance [69]. In the rat, four heterozygous missense mutations in VKORC1 were
reported in Warfarin resistant cases. In addition, one homozygous point mutation in
exon 3 has been found in two unrelated index cases of a combined deficiency of
vitamin K-dependent clotting factor type-2 (VKCFD2) [69].
They also studied the over expression of wild-type VKORC1 and the form carrying
the VKCFD2 mutation and noticed a marked increase in VKOR activity and
increasing Vitamin K production by approximately 14 to 21 times compared with
untreated or mock-transfected cells [68], [69]. These discoveries helped in the
understanding of Warfarin resistance in humans and rodents.
The purification of recombinant human VKORC1 protein from baculovirus-infected
insect cells was reported in by Chu who demonstrated that it was possible to convert
Vitamin K epoxide to Vitamin K; and Vitamin K to reduced Vitamin K through the
enzymatic function of a single VKORC1 polypeptide [73]. It was thought that
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VKORC1 was subunit 1 of the enzymatically functional complex involved in
Vitamin K recycling. However, it was found that the gene product of VKORC1 was
enzymatically active on its own which led to the informal shorting of the name to
VKOR [74].
Genetic variations in VKORC1 was associated with significant inter-individual and
inter-ethnic variability in the dosage of Vitamin K antagonists (Coumarin) [75].
Studies on VKORC1 enhanced our understanding of the Vitamin K cycle and led to
improved clinical practice [76].

1.6 The Global Prevalence of the Clinically Relevant VKORC1 Alleles and
Genotypes
It is well known that Warfarin dosage and responses are greatly affected by genetic
variation in the VKORC1 gene. In addition, genetic variation in this gene results in
different phenotypes such as resistance to Warfarin (Warfarin resistance, WR) or
pathological conditions known as multiple coagulation factors deficiency type 2
(VKCFD2) that can cause a rare bleeding disorder [69], [77].
The discovery of a haplotype structure in the human genome and the ability to define
SNPs, facilitated genotyping studies at significantly reduced costs. There is a need to
take into account not only differences between the genotypes of individuals but the
differences in genotypes between different populations to improve health care [78].
In Warfarin resistant patients, several rare mutations in the VKORC1 gene lead to
amino acid changes in VKORC1 proteins. These rare mutations are not reported in
the general population [69].
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The genetic basis of the large inter-individual variability among Warfarin patients
investigated by Rieder, who described the coding region variants of VORC1 that are
highly detrimental and cannot explain Warfarin dosage variation [79] .
In addition, a study was conducted to determine whether polymorphisms in noncoding regions of the VKORC1 contribute to variability in the maintenance dose of
Warfarin and found that SNPs in non-coding regions are associated with Warfarin
dosages across the normal dose range (2 to 10 mg per day) [79]. This opened the
door to further study other regulatory polymorphisms in the VKORC1 that could
possibly change Warfarin dosage requirements. Consequently, SNPs in the VKORC1
non-coding region were found in various populations [79], as illustrated in figure 6.

Figure 6. VKORC1 gene structure with the relevant non-coding variants.
The mechanism of how these SNPs in non-coding affect Warfarin dosage variability
were thought to be through the effect on the mRNA levels [79].
The first SNP (C6484T, rs9934438 (608547.0008) or 1173C>T) was reported to
associate with low Warfarin doses. This SNP is located in the first intronic region of
the VKORC1 gene and the wild type C/C genotype requires significantly higher
doses compared to the T/T genotype [43].
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This variant is in near perfect linkage disequilibrium with promoter region variant
G3673A (rs9923231) [43]. Since the frequency of C6484T is approximately similar,
if not identical, to the frequency of G3673A, some researchers consider this variant
inert but it is still used frequently in haplotype determination of the VKORC1 gene as
marker of SNP [52].
Warfarin sensitivity in patients with lower doses is frequently associated with
promoter region single nucleotide polymorphism -1639G-A (608547.0006). On the
other hand, VKORC1 variant rs7294 (G9041A), or 3730G>A are reported to be
associated with Warfarin resistance in patients who need higher doses compare to the
wild type [66].
Two SNPs in the non-coding region of the VKORC1 gene, rs9934438 (608547.0008)
and rs9923231 (608547.0006), were the best predictors of Warfarin dosage through
transcriptional mechanisms that alters expressions of the Warfarin target receptor
VKORC1 [79]–[81]
The-1639G-A (rs9923231) variation is associated with lower Warfarin dosages,
Warfarin sensitivity and higher risks of bleeding [66]. Individuals with the A/A
genotype (group A, haplotype 2* mainly) required a lower dose than those with the
A/G or G/G genotypes. The G allele comes with a 44% increase in activity when
compared with the A allele [82].
The rs7294 (G9041A), is a variant associated with high warfarin dosages that occurs
at the 3′UTR of VKORC1 gene [43], [83]. It does not usually occur with the
1173C>T and 3673G>A variant allele haplotype [43].
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A patients with (rs9923231) and 1173T (rs9934438) variant allele was reported to
have a low dose of about 24-26 mg/week while patients with wild type required a
dose of 36mg/week [26].
A high dosage reported for patients with (rs7294) allele variants of approximately 40
mg/week as a mean dose [26], [83]. This indicates the effect of VKORC1 in noncoding variants on Warfarin pharmacodynamics studies that concluded that VKORC1
variation can explain 25% of the variability in Warfarin dosage [79].
A significant correlation of the relevant SNPs in the VKORC1 with approximately
30% of Warfarin dosage variation has been determined in a genotyping study of 201
patients using Warfarin. These findings indicate that the VKORC1 genetic variation
plays a greater role in dose requirements compared to CYP2C9 which explains only
12% of the variation in dose requirements [26]. SNPs in non-coding regions of the
VKORC1 gene classify Warfarin patients according to their required dose of
Warfarin to safely achieve the target INR [79].
According to this classification, patients with SNP (rs9923231) have low Warfarin
dose-requirement with approximately 2.7 mg per day for the A/A genotype that is
mostly distributed in Asian Americans. High dosage groups with rs7294, A/A
genotype need 6.2 mg per day which is widely distributed among African Americans
and an intermediate dose of 4.9 mg per day for patients with heterozygosity in both
SNPs (rs7294 and rs9923231) [79]. There are continuous efforts to identify VKORC1
haplotypes but the nomenclature is still varied [79].
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1.7 Warfarin Usage in the UAE
There are a limited number of clinical research studies on Warfarin usage in the UAE
and no pharmacogenetics studies so far. There was a study in 2012 conducted in AlAin to evaluate patient and staff compliance with Warfarin usage guidelines and to
assess the overall practice and patient outcome [84]. The authors reported that at AlAin Hospital, each year there are 800 cases (~27 new) of patients on Warfarin
including Emiratis and expatriates. Indications for Warfarin usage among those
patients were 35% for atrial fibrillation, 28% for deep vein thrombosis, 20% for
prosthetic heart valves and 12% for stroke and dilated cardiomyopathy.
The authors found that regular INR monitoring was carried out for only 23% of the
patients. They also found that 73% of the patients had a stable INR while 20% had a
high INR and 7% had lower values than the therapeutic target. 22% of patients have
been admitted to the emergency ward from Warfarin patients with 9% of the cases
unrelated to Warfarin use. In addition, side effects such as abnormal bleeding have
been frequently reported among patients with a high INR. Furthermore, hematemesis
was reported for 25.3%, shaving cuts for 21.8%, bleeding gums for 19.9%, bleeding
wound for 14.6% and melena in 11.3% of the patients [84].
A lack of genetic studies related to Emiratis on Warfarin prompted us to carry out
this project.
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CHAPTER 2: STUDY RATIONALE, AIM AND OBJECTIVES

2.1 Rationale
Warfarin is a drug with a low therapeutic index where small dose changes may result
in serious side effects or treatment failure. It is well known that the genetic makeup
of the individual contributes to their response to medication including Warfarin. A
significant proportion of patients receiving the standard dose of Warfarin may either
not respond to treatment or exhibit bleeding as a side effects. Genetic variations in
the VKORC1 gene play a major role in Warfarin dosages and are responsible for
about 30% of the dose variation. Therefore, it can be considered to be the major
genetic determinant. Despite their importance for determining the optimal starting
dose for patients, no genetic studies have been carried out on Emiratis in relations to
Warfarin use. Therefore, the purpose of this thesis is to start to fill this gap in our
knowledge for the local Emirati population.

2.2 Aim and Objectives
2.2.1 Aim
Identify the alleles and genotypes frequencies among Emiratis for two important
SNPs (rs9923231 and rs7294) in the VKORC1, the gene encoding the cellular target
for Warfarin treatment.
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2.2.2 Objectives
To achieve the above aim, the thesis objectives are:
1. Recruit and obtain blood samples from healthy Emirati donors and patients
receiving Warfarin as part of their healthcare.
2. Isolate and quantify genomic DNA from each subject using standard molecular
techniques.
3. Genotype those samples for two SNPs, rs9923231 and rs7294 SNPs, in the
VKORC1 gene using PCR and direct Sanger DNA sequencing.
4. Determine the SNPs allele and genotype frequencies among healthy Emiratis
subjects and patients receiving Warfarin.
5. Correlate the determined allele and genotype frequencies with drug response in
patients.
6. Generate genetic data that might be deposited/ shared with health care providers in
the UAE and/or with international databases.
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CHAPTER 3: MATERIALS AND METHODS

3.1 Blood Sampling
Blood samples were collected from two groups: the first group consisted of 96
unrelated UAE nationals who suffered from a coagulation disorder and are being
treated with Warfarin as part of their care. This group of subjects was recruited from
patients attending the INR clinic at Tawam Hospital, Al-Ain, UAE. The second
group consisted of 117 healthy Emirati subjects from Al-Ain and Abu Dhabi.
All the individuals had read the information sheet and signed informed consent forms
to participate in the study. About 10ml of peripheral venous blood was collected.
Five ml of the blood sample was placed in an EDTA tube (containing an
anticoagulant) to be genotyped. The subjects also completed a questionnaire and
their

medical

files

were

reviewed

to

examine

the

fulfillment

of

the

inclusion/exclusion criteria. This study protocol was carried out at the laboratories of
the College of Medicine and Health Sciences at UAE University. In addition, it was
approved by the ethical committee for human research in the Al-Ain District (CRD
261-Protocol No. 13/38).

3.2. Extraction of DNA from Peripheral Leukocytes
Deoxyribonucleic acid (DNA) was extracted from an ethylene-diamine-tetra- acetic
acid (EDTA)-anticoagulated blood using a whole blood extraction kit (Flexigene
DNA isolation kit (250)- Applied Biosystems). The isolated genomic DNA was
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stored in sterile vials at 4 oC until analyzed. DNA samples were kept at – 20 oC for
long term storage.

3.3. Primers Design
Primers for amplifying the relevant parts of the VKORC1 gene were designed using
primer3

http://primer3.ut.ee

and

were

custom

made

by

Metabion

Inc

(http://www.metabion.com). The list of PCR and sequencing primers are listed in
Table 1.

SNP

Forward Primer

Reverse Primer

rs9923231

3`GCCAGCAGGAGAGGGAAATA5

3`AGTTTGGACTACAGGTGCCT5`

rs7294

3`GGCTTACGCACGTATTCC5`

3`GGTTCAGACTTGGCTGATTG5`

Table 1. Sequences of the oligonuceloetide primers used for the PCR amplification
and genotyping of the two VKORC1 SNPs

3.4 Polymerase Chain Reaction (PCR)

PCR amplification (thermal cycling) conditions were as follows: a single
denaturation cycle of 5 minutes at 95 oC followed by 40 cycles of 95 oC for 2
minutes. The exact annealing temperatures and times are listed in table 2 and then at
72 oC for 2 minutes. This was followed by a single cycle of 7 minutes at 72 oC.
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Primer Name

Annealing
Temperature (oC)

Annealing Time
(Sec)

Product Size
(pb)

rs9923231

58

30

290

rs7294

60

45

659

Table 2. Annealing temperatures optimization and expected product sizes.

3.5 Analysis of PCR Amplicons by Agarose Gel Electrophoresis .

The two VKORC1 specific products (amplicons) from each subject were separated
by 0.6% agarose gel electrophoresis to ensure a good DNA quality was produced
before sequencing. The promoter region SNP (rs9923231) is expected to produce
DNA band (A)of 290 bp whereas SNP (rs7294) will give a Size of 659 bp (B) as
presented in Figure 7
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Figure 7. Agarose electrophoresis analysis of representative PCR reactions for the
two SNPS and primers of experiment and their approximate base pairs sizes.

3.6 DNA Sequencing
DNA was sequenced using a dideoxy sequencing (chain termination of Sanger)
method with a 3130Xl Genetic Analyzer (applied Biosystems). The procedure
involved cleaning up the PCR reactions using an Exo-SAP-IT treatment prior to
Sanger DNA sequencing.

3.6.1 ExoSap-IT Treatment
The ExoSAP–IT was used for cleaning up the PCR products. This technique has
been shown to be suitable for cleaning up PCR products of less than 100 bp to over
than 20kb without any sample loss, by removing the unused excess primers and
nucleotides through a degradation by enzyme action. The method in this experiment
was carried out by 1.25 l of purified PCR product to undergo enzymatic purification
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with 0.5 µl of an ExoSAP –IT enzyme mixture at 37 oC for 15 minutes. This was
followed by heating at 80 oC for 15 minutes to inactivate the exonuclease and SAP
enzymes.

3.6.2 DNA Cycle Sanger Sequencing
The cycle sequencing was carried out by preparing a sequencing mix containing 1l
(3.2 pmol) of sequencing primers, 4l of ready reaction premix 2.5X (Big Dye
Terminator Cycle Sequencing Kit Applied Biosystems), 1 l of BigDye Terminator
v.3.1 sequencing buffer (5X) and 20ng/ ml template, miliQ water was added to form
20l reaction. The tubes were placed in a thermal cycler and an initial denaturation
step was performed with a rapid thermal ramp to 96 oC for 1 minute, then the
following steps were repeated up to 25 cycles:


A.rapid thermal ramp to 96 oc (96 oc for 10 seconds).



A rapid thermal ramp to 50 oc (50 oc for 5 seconds).



A rapid thermal ramp to 60 oc (60 oc for 4 minutes).



A rapid thermal ramp to 4oc.



Purification of the sequencing products.

3.6.3 DNA Sequencing Purification Step
If the dye terminators are not removed completely before the electrophoresis step, the
signal from the dyes will be obscured due to an excess of DNTPs. This method is
suitable when using Big Dye Terminators v3.1 as it produces consistent signaling
and it is good at getting a 20l sequencing reaction in 96-well reaction plates
following a brief spinning after removing the reaction from the thermal cycler. 5l of
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125 mm EDTA is added to the 60 l of 100% ethanol in each well and the mixture is
sealed and inverted 4 times before being incubated for 15 minutes at room
temperature. This was then immediately centrifuged at 3000 xg for 30 minutes
(Sigma 2-16 pk) and the plate was inverted and spun at up to 185 xg then removed
from the centrifuge. A 60 l of 70% ethanol was also added to each well then spun
again at 1650 x g for 15 minutes with the centrifuge set at 4 oC. This was followed by
inversion and spinning up to 185xg for 1 minutes before removal from the
centrifuge.

3.6.4 Formamide Treatment
Hi-Di Formamide is a highly deionized formamide formulated with stabilizers and
ready for use as an injecting solvent in DNA analysis methods. The samples were
resuspended in 15 μl formamide (Hi-Di TM formamide, Applied Biosystems),
denaturated at 95 oC for 2 minutes and then kept on ice for 2 minutes until
sequencing.

3.6.5 Sequencing Data Interpretation and Genotype Calling
For each patient the chromatograms of the nucleotide sequence were aligned with the
original VKORC1 sequence (ENST00000394975) using the chromas lite program in
order to detect the presence of SNPS/mutations as well as to define each patient`s
genotype.
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3.7 Statistical Analysis
SSPS and Graph Pad programs were used to apply selected statistical analysis; we
used chi-square tests for non-parametric variables to compare between frequency
results, while multiple linear regression models, ANOVA and Spearman analysis
were used to study dose-genotype relations.
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CHAPTER 4: RESULTS

4.1 Description of Study Sample
This study involved two groups of UAE nationals. The first group included 117
unrelated healthy subjects as controls and the second group consisted of 96 patients
who were on Warfarin treatment for at least two months. Patient characteristics are
summarized in table 3.

Age
Gender

Indication of
Warfarin

Median Age

64 year

Average Age

59 year

Standard Deviation (SD)

19.73 year

Male

48(50%)

Female

48(50%)

Atrial Fibrillation

46(48%)

Deep Vein Thrombosis

15(16%)

Valve Replacement

26(27%)

Antiphospholipid Syndrome

3(3%)

Cardio Vascular Shunt

1(1%)

Cerebella Ataxia

1(1%)

Artery Thrombosis

1(1%)

Pulmonary Embolism

2(2%)

Valve Disease

1(1%)

Table 3. Characteristics of the recruited patients
Informed consent was obtained from each participant. This study was approved by
the ethics committees of each participating institution. Patient information (indicators
of Warfarin use, maintenance doses and INR values etc.) were collected from
Tawam Hospital medical records as of 23/09/2014.
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In this study we recruited equal numbers of patients of both genders: 48 females and
48 males. The mean age was 64 and the median age was 59. The age ranged from 17
to 99 years with a standard deviation of 19.73 years.
Warfarin was prescribed for patients for different pathological conditions with Atrial
Fibrillation (AFIB) at 48%; Deep Vein Thrombosis (DVT) at 15%; Antiphosholipid
Syndrome (APS) at 3%; After Mitral Valve Replacement (MVR) and Aortic Valve
Replacement (AVR) for 27%; 2% for Pulmonary Embolism (PE), while Valve
Disease, Arterial Thrombosis, Cerebella Ataxia, Cardio Vascular Shunt each
constituted 1% of the total use of Warfarin.
The target INR range for 67% of the patients was 2.5-3.5; 32% with an INR target
range of 2 -3 where only 1% have a target range of 1.5-2.
The average Warfarin dosage of patients was 4.7 mg/day with an SD of 2.47 and a
median dose of 4.5 mg/day. The highest dosage was 15 mg/day and the minimum
dose was 0.5 mg/day.

4.2. VKORC1 Genotype and Allele Frequencies
Using PCR amplification and direct DNA sequencing, we genotyped each subject
from both groups for two VKORC1 gene variants relevant to Warfarin dosage. The
two variants are the promoter region variant rs9923231 and the 3` UTR region
variant rs7294, as listed in table 9.
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Nucleotide position
SNP

Nucleotide
change

Gene region

Genomic

cDNA

rs9923231

3673

c. -1639

G>A

Promoter

rs7294

9041

492+134

G>A

3'-region

Table 4. Description of the studied polymorphisms (SNPs) of the VKORC1 gene.
(cDNA: coding DNA, rs: reference subgroup)
Rs7294 was selected as per the literature due to its key role in Warfarin resistance
cases, while variant SNP rs9923231 was selected as per the USA Food and Drug
Administration (FDA) recommendations [85]; as shown in table 5.

Drug Link in
Drugs@FDA

Warfarin

Referenced Subgroup

VKORC1 rs9923231
A allele carriers

Labeling Sections with
Pharmacogenomic Information

Dosage and Administration
Clinical Pharmacology

Table 5. Food and Drug Administration (FDA) labeling recommendations for
Warfarin

4.2.1 Determination of the VKORC1 rs9923231 Genotypes and Alleles
Frequencies
VKORC1 rs9923231 SNP genotype and allele frequencies among patients and
controls are presented in table 6.
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Genotypes

Alleles

Controls

Patients

UAE

N=117

N=96

N=213

(%)

(%)

(%)

GG

30(25.6)

24(25)

54(25)

GA

58(49.6)

46(47.9)

104(49)

AA

29(24.8)

26(27.1)

55(26)

G

118(50.4)

94(49)

212(49.8)

A

116(49.6)

98(51)

214(50.2)

Table 6. Genotypes and alleles frequencies among patients and controls for
rs9923231 .(N indicates the total number of study subjects in both controls and
patients)

We compared the percentage of the three genotypes (GG, GA and AA) between both
groups (control and patients) as listed in table 1

Controls

Patients

Genotype

n=117

n=96

GG

55.6%

44.4%

GA

55.8%

44.2%

AA

52.7%

47.3%

Table 7. Percentage of rs9923231 SNP Genotypes among both groups, controls and
patients.
(N indicates the total number of study subjects in both controls and patients)
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There are no statistically significant differences in the prevalence of GG, GA, AA
genotypes for rs9923231 between the control group and the patients. We used a chisquare test to investigate (chi-square= 0.1459, df = 2, p-value = 0.9296). The aim of
this test was to investigate if there was a difference in genotype frequencies between
healthy control groups and patients.
The genotype frequencies of rs9923231 in the 213 UAE participants are presented in
(table 9). They show that the genotypes GG and AA have similar distributions of
25% and 26% respectively. On the other hand, the heterozygous genotype GA
frequency was 49 %. The allele frequencies for rs9923231 variants are presented in
Table 9 with almost equal frequencies of 49.8% for the G allele and 50.2% for the A
alleles.VKORC1 rs9923231 SNP genotype frequencies among patients and control
subjects are presented graphically in Figure 8.

Figure 8. Graphical presentation of genotype frequencies among patients and control
for rs9923231.
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In addition, we compared the results from this study to data from other populations
as listed in table 8

UAE
VKORC1
n=213
SNP

Genotype

GG

Saudi
n=131

[86]

25

37.4

Iran

China

Caucasian

Indian

n=81

n=178

n=22

n=43

[87]

[88]

[89]

[90]

15.8

0.6

31.8

83.8

15.7

50.0

9.50

83.7

18.2

6.80

7

G-1639A
GA

49

39.7

57.1
4

AA

26

22.9

26.9
8

Alleles

G

49.8

57

44.4

8.42

56.82

88.4

Frequency

A

50.2

42.7

55.6

91.57

43.18

11.6

Table 8. Ethnic distribution of rs9923231 Genotypes and alleles in various
populations.
The graphic representation of ethnic distributions of rs9923231 genotype
frequencies is shown in figure 9 and allele frequencies in figure 10
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Figure 9. Ethnic distribution of rs9923231 genotypes

Figure 10. Ethnic distribution of the rs9923231 alleles
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We used a chi-square test (nonparametric test for discrete variables) to compare the
differences between the allele frequencies in populations shown in table 8; the value
of p<0.05 was considered as statistically significant. Statistical analyses were
performed applying the Graph Pad program.The UAE population when compared to
the Chinese Population had a p value of <0.001. The UAE population when
compared to the Indian Population had a p of <0.001. For the other populations, there
were no significance differences in allele frequencies

4.2.2 Determination of the VKORC1 rs7294 Genotype and Allele Frequencies
VKORC1 rs7294 SNP genotype and allele frequencies among patients and control
subjects are presented in table 9..

Controls

Patients

UAE

N=117

N=96

N=213

(%)

(%)

(%)

GG

54(46.2)

40(41.7)

94(44)

GA

46(39.3)

48(50)

94(44)

AA

17(14.5)

8(8.3)

25(12)

Alleles

G

154(66)

128(66.7)

282(66)

Frequency

A

80(34)

64(33.3)

144(34)

SNP

Genotype

G9041A
rs7294

Table 9. Genotype and Allele frequency for rs7294 for controls and patients.

We compared the percentage of the three genotypes (GG, GA and AA) for rs7294
between both groups (control and patients) as listed in table 11.
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Controls

Patients

n=117

n=96

GG

57.4 %

42.6 %

GA

48.9 %

51.1 %

AA

68.0 %

32.0 %

Genotype

Table 10. Percentage of rs7294 SNP genotypes among both control and patient
groups.
(N= total number of subjects in both control and patient groups)

Figure 11. Graphic presentation of genotype frequencies among patients and control
subjects for rs7294.

The genotype frequency of rs7294 for the total study sample of 213 UAE locals is
shown in table 6. It shows differences in the distribution of the homozygous GG and
AA genotypes with frequencies of 44% and 12%, respectively. On the other hand,
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the heterozygous GA genotype is in equal distribution with the homozygous
genotype 44 %. Allele frequencies are shown in table 9 with the G allele being
present at frequency of 66% ,while the A allele is present at a frequency of 34%. We
compared results from this study to data from other populations as listed in table 11.

UAE
VKORC1

Genotype

n=213

SNP

Chinese Caucasian

Indian

n=551

n=22

n=43

[91]

[89]

[90]

GG

99

81.3

43.5

8.1

GA

99

18.3

47.8

18.9

AA

13

0.4

8.7

73

Alleles

G

66

90.5

67.4

18.6

Frequency

A

34

9.5

32.6

81.4

G9041A
rs7294

Table 11. Ethnic distribution of the rs7294 genotypes and alleles frequencies.
Graphic representation of ethnic distribution of rs7294 genotype frequencies is
shown in figure 12 and the allele frequencies in figure 13.
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Figure 12. Ethnic distribution of rs7294 genotypes

Figure 13. Ethnic distribution of rs7294 alleles.
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We used a chi-square test (nonparametric test for discrete variables) to compare the
differences between the allele frequencies in populations as shown in table 11.The
value of p<0.05 was considered as statistically significant. Statistical analyses were
performed applying the Graph Pad program.
The UAE population when compared with the Indian and Han-Chinese population
had a p<0.001.There were no significance differences in allele frequencies with
European populations.

4.3 The Rs9923231 and Rs7294 VKORC1 Variants Genotypes Associated with
Warfarin Doses Among Emirati Patients
A Spearman correlation coefficient statistical analysis was selected to test the
correlation coefficient in each SNP.
We used the Graph Pad to study the correlation between each SNPs and the daily
maintenance Warfarin dose for patients included in this study. In summary, both
SNPs shows significant correlations with dosages (P<0.05) as shown in figures 14
for rs9923231 genotypes and figure 15 for rs7294 genotypes.
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Figure 14. Spearman Correlation Coefficient between rs9923231 genotypes and daily
Warfarin dosage.

Figure 15. Spearman Correlation Coefficient between rs7294 genotypes and daily
Warfarin dose.
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We used a scatter Plot to graphically represent each genotypes relation to dosage.
Both SNPs were correlated significantly to daily Warfarin dosage (P-value<0.05) as
shown in figures 16 and 17.

Figure 16. Scatter Plot representation of rs9923231 genotype relation to daily
Warfarin dose (*** means P-value < 0.05).

The GG genotype shows a higher dosage compared to GA and a lesser dosage to the
AA genotype. While for rs7294 the higher dose is associated with the AA genotype.
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Figure 17. Scatter Plot representation of rs7294 genotype relation to daily Warfarin
doses (*** means P-value < 0.05).

In addition, we used a Boxplot method to represent patient dose variation in relation
to genotype and to show the dispersion (the spread) of doses among each genotype
for SNPs. This data is shown in figures 18 and 19.
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Figure 18. Boxplot of mean daily Warfarin doses for different VKORC1 genotypes
(SNP rs9923231).

The horizontal line indicates the median; the box covers 25–75% percentiles. Points
outside this show up as outliers. In all 96 individuals were genotyped for rs9923231
genotyping. The maintenance dose of Warfarin was related significantly to genotype
since AA genotype required a lesser dose compared to the intermediate dose for a
GA genotype and a relatively higher dose compared to the GG genotype.
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Figure 19. Boxplot of mean daily Warfarin doses for different VKORC1 genotypes
(SNP rs7294).

The horizontal line indicates the median, the box covers 25–75% percentiles. Points
outside this show up as outliers. In all 96 individuals were genotyped for rs7294
genotyping. The maintenance dose of Warfarin was related significantly to genotype
since GG genotypes required a lesser dose compared to an intermediate dose for GA
genotypes and a relatively higher dose for AA genotype carrying patients5
Furthermore, we used a multiple liner regression analysis, where daily Warfarin
dosages in milligrams (mg) was the dependent variable and the genotype was an
independent variable and controlling for other factors such as age and gender. Using
VKORC1 rs9923231 genotypes, age, and gender.
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Linear regression analysis shows that there is significant relationship between the
rs9923231 SNP genotypes (AA, GA and GG).
The average dose for AA genotypes is (2.61 mg /day SD 1.022), for the GA
genotype it is (4.74 mg/day SD 1.72) and for GG genotype it is (7 mg/day SD 2.796).
the average age of patients was 59 (SD 19).
We found that there was a significant relationship between age and dosage (P-value
< 0.01) but to a lesser extent than for genotype while no relationship with gender to
daily Warfarin dose (P-value = 1). This data is shown in table 12.

Variable

Daily dose P value

AA

< 0.001

GA

< 0.001

GG

< 0.001

Age

< 0.01

Gender

1

Table 12. Multiple linear regression models with rs9923231 genotypes, age, and
gender.
(Multiple R-squared: 0.477, adjusted R-squared: 0.4541, degree of freedom (DF): 91,
p-value: 3.518e-12. F-statistic: 20.75)

For rs7294 we also used a multiple linear regression model and results are shown in
table 12
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Factors

Daily dose P-Value

GG

>0.001

GA

>0.001

AA

>0.001

Age

>0.001

Gender

1

Table 13. Multiple linear regression models with rs2794 genotypes, age, and gender.
)Multiple R-squared: 0.2797, adjusted R-squared: 0.248, F-statistic: 8.832 on 4, pvalue: 4.525e-06(.

Using a linear model where dose is the dependent variable and rs2794 genotypes are
the independent variable, and controlling for other factors such as age and gender, we
found that there was a significant relationship between the rs7294 SNP genotype and
the dose taken (P-value = 0.0003). The average Warfarin dose required for the GG
genotype is 3.6 mg/day (SD 2.5), the GA genotype is 5.3 mg/day (SD 2) and for the
AA genotype it was 6.7 mg/day (SD 2.6). Age significantly correlated to dose (Pvalue >0.001) while gender was found not to be correlated (P>1).
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CHAPTER 5: DISCUSSION AND CONCLUSIONS
Allele and genotype frequencies for SNPs rs9923231 and rs7294 in the VKORC1
gene were found to be in a Hardy-Weinberg equilibrium among the study sample of
213 UAE nationals. There were no significance differences in the prevalence of GG,
GA and AA genotypes for rs9923231 variants between the patients and control
groups as determined by a chi-square test (p-value = 0.9296). Similarly there was no
significant difference between the two group for the rs7294 variant (chi-square test
for GG, GA and AA genotypes (p-value = 0.1842). This means, as expected, that
both SNPs distributed equally between control and patient groups without any
significant difference associated with any pathological condition.
The genotype frequency for the rs9923231 variant in the total study sample of 213
local UAE participants for homozygous GG and AA are presented in Figure 8 and
Table 9. They show similar distributions of 25% and 26% respectively while the
distribution of the heterozygous GA genotype was higher at 49%. Allele frequencies
for rs9923231 are shown in Table 6 and indicate no differences in G and A allele
frequencies at 49.8% and 50.2%, respectively.
The genotypes frequency for the rs7294 variant in the total study sample of 213
subjects is shown in table 9 and indicates some differences in the distribution of
homozygous genotypes (GG and AA) of 44% and 12%, respectively, while the
heterozygous GA genotype is in equal distribution with homozygous genotype at
44%. We found that the allele frequency for G (66%) more than for the A allele
(34%) as shown in table 9.
Warfarin dosages vary among Emirati patients with doses ranging from 0.5 mg to 15
mg of Warfarin per day (figure 16, and figure 17). This wide variation in dose
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requirements is a major justification for carrying out this type of genetic study among
Emiratis.

Genetic causes are likely to be contribution factor in a significant

proportion of this variability, as demonstrated by many studies on Warfarin dosage
[92]. Genotypes for VKORC1 SNPs correlate significantly with daily Warfarin doses
according to the results of this study (figures 14 and15). The rs9923231 and rs7294
are closely associated with dosage with a p-value of < 0.001 for both SNPs (figures
14 and15). Therefore, we can conclude that the rs9923231 and rs2794 are good
predictors of Warfarin maintenance dosage as shown in the Boxblot analysis in
figures 18 and 19. For the rs9923231 homozygous AA genotype a smaller dose is
required (2.6 mg/day, SD 1.022) compared to the heterozygous GA genotype (4.75
mg/day, SD1.7). A higher dose is required for the homozygous GG genotype (7
mg/day, SD 2.7) with a P-value < 0.0001(3.518e-12).
A recent study in Al- Ain evaluated the effects of other factors such as age, gender,
body mass index (BMI), indications of Warfarin treatment, patient compliance in
maintaining stable INR indicators of correct dosage, etc. They found that gender, and
BMI have no effect while age, co-morbid status, and compliance were found to
significantly affect the coagulation profile of patients [84]. Although age and gender
both have been studied in previous studies, we included it in this study to show have
direct effect on dosage but not on INR. In our study age significantly affected
Warfarin dosage as demonstrated by the multiple regression model of analysis (tables
12, 13). Gender on the other hand had no significance effect (table 12, 13).
Generally there is a focus on rs9923231 (-1639 G/A) variant which is located at the
second nucleotide of an E-box (CANNTG) of the 5` untranslated regions (5`UTR) of
the VKORC1 gene [82]. This variant plays a key role on the activity of the promoter
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region of the VKORC1 gene and it is believed to be a causative SNP for low dose
requirement phenotypes in some patients [52]. The activity of the G allele is 44%
higher than the A allele in this position [82]. Polymorphism in rs9923231(-1639
G/A) shows an interference with the mRNA expression in liver samples since it is
associated with variable levels of mRNA. The A allele disturbs the binding of
transcription factors to the VKORC1 gene promoter region leading to a decrease in
active mature copies of the VKORC1 protein activity [82].
According to the literature, patients with the G allele require a daily dose of 5
mg/day compared to 3.5-3.7 mg/ day for patients with the A allele [26]. In our study
daily doses of Warfarin were approximately 2.6 for homozygous patients with the A
allele and approximately 7 mg/day for patients with the homozygous G allele
(Figures 16 and 18).
Another study has reported that patients with the A allele have a Warfarin dose
ranging from 2.9 up to 3 mg per day, while patients with the homozygous G allele
range from 5.5 up to 6 mg/day [79].
The frequencies of the rs9923231 (-1639 G/A) genotypes and alleles have been
widely studied in different populations [52].

For example, 90% of the Asian

population have the A allele and therefore patients of Asian origin require lower
doses of Warfarin [52]. On the other hand, 40% of some caucasian populations have
the A allele. It was postulated that rs9923231 is the best predictor of Warfarin dose
requirements especially in the initial stages of Warfarin therapy [79].
It is worth mentioning that the rs9923231 variant is the only SNP mentioned in FDA
recommendations for labeling Warfarin leaflets amongst all the other important
SNPs in the VKORC1 gene. However, many studies have shown the importance of
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other non-coding SNPs in the VKORC1. However, these SNPs are mostly in perfect
linkage disequilibrium with rs9923231 [79]. Based on several studies, the FDA has
recommended genetic testing on Warfarin for the VKORC1, rs9923231, A allele
carriers and for the CYP2C9 gene haplotype

(http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083
378.htm) [85].
Another SNP located in the 3′UTR of theVKORC1 rs7294 or as it called in the
literature G9041A, or 3730G>A. It is not correlated with any other SNP in
theVKORC1 gene [79]. Generally this SNP is not found in the same haplotypes as
the G3673A. This is the reason for selecting this SNP in our study although it was
not recommended by the FDA. Patients with rs7294 alternative variants may require
higher doses of Warfarin [43].
In this current study, rs7294 as shown in figure 15 and figure 17 for the homozygous
AA genotype, required higher doses (6.7 mg/day, SD 2.6), while the heterozygous
GA genotype required 5.3 mg/day, (SD 2) a lesser dose was required for
homozygous GG genotypes (3.61 mg/day SD 2.5) With a P-value of < 0.0001
(0.0003).

Therefore, findings in this study support previously published data

confirming a higher dose requirement for individuals with the homozygous A allele
genotype (5.7 mg/ day) [26].
It was suggested that 6-37% of the variation in Warfarin dosage among individuals is
due to SNPs in the VKORC1 gene [79], [81], [85]. It was well documented that the
VKORC1 polymorphism highly influences Warfarin dosage and in some cases may
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cause resistance at the A allele in rs7294 variants or sensitivity with A alleles of the
rs9923231 variant [79], [81].
This is first genetic study among Emiratis regarding VKORC1 allele and genotype
frequencies. Our data suggests that SNPs are very important for Warfarin
maintenance dosage and therefore they are likely to be of clinical significance
(Figures 14 and 15).
Different ethnic groups require different Warfarin doses. For instance Chinese
individuals, on average, require lower dose compared to African Americans [93],
[94].
There have been many trials on new medication to replace Warfarin since its
approval in 1954. This is mainly because of the many reports of side effects observed
in patients receiving this medication. However, surveillance studies on complications
and pharmaco-epidemiology of Warfarin are not currently available in the UAE.
There is generally a lack of drug-drug and food-drug interaction studies locally. For
instance, it was not easy to find reported cases of side effects associated with
Warfarin treatment, such as Inpatient hospitalization due to Warfarin, patient’
outcomes in selecting a dosage of Warfarin depending on non-genetic factors in
Emiratis. Our data indicates that genotyping will be useful and most probably cost
effective when initiating Warfarin treatment.
The two variants tested are useful but a clearer and more accurate picture can be
observed if other parts of the VKORC1 gene and CYP2C9 gene are studied in more
depth in Emiratis. It is also important to look at non-genetic factors involved in
Warfarin dose requirements among Emiratis such as lifestyle, diet, chronic use of
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other medications, food supplements and herbal remedies used by the local
population.
Our data indicates that pharmacogenetic testing of rs9923231 and rs7294 variants is
highly relevant to the maintenance of Warfarin dosage among Emirati patients on
this medication. Implementation of genetic testing, at least for these two variants, is
likely to have a direct effect with potential benefits to the patients and healthcare
system in UAE. This is also likely to have a direct impact on patient safety and
reduce suffering and cost.
The evidence provided here demonstrates that genetic factors in the VKORC1 gene
are significant contributors to Warfarin dosage and, as a result may be employed to
reduce the risk of developing side effects such as bleeding or thrombosis.
Having said that, we believe that it is important to sequence the rest of the VKORC1
gene to study the haplotypes and perhaps examine for the presence of private variants
in this gene among Emiratis. It is also important to study the variants of the CYP2C9
gene.
In conclusion, this is the first study reporting the influence of genetic factors such as
VKORC1 polymorphisms (rs9923231 and rs7294) in Emiratis. We also report the
frequencies of alleles and genotypes of these SNPs allowing us to compare with
other populations which might be useful for genealogical studies.
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